Myomo, Inc. Presents at 2017 Marcum MicroCap Conference

CAMBRIDGE, Mass., Jun 13, 2017 (BUSINESS WIRE) —

Myomo, Inc. (NSYE MKT: MYO) (“Myomo” or the “Company”), a commercial
stage medical robotics company, today announced that its Chairman and
CEO, Paul R. Gudonis, will be presenting at the 2017 Marcum MicroCap
Conference at the Grand Hyatt Hotel in New York City.

The Myomo presentation is scheduled to begin at 11 A.M. EDT on Friday,
June 16. A live audio webcast of the presentation will be available
online at
An archive of the event will also be available for those unable to
listen live.

Any investors attending the conference that wish to meet with Mr.
Gudonis for a one-on-one meeting should schedule through the online
meeting requests system.

The Marcum MicroCap Conference (
is a nationally recognized forum for publicly traded companies with less
than $500 million in market capitalization to network with fund managers
and high net worth investors who focus on small cap equities. More than
2000 investors and other participants from every segment of the microcap
marketplace attend each year, including venture and lower middle-market
private equity investors, institutional investors, directors, investment
bankers, and buy- and sell-side analysts, as well as senior executive
teams from presenting companies and service providers to the microcap

The conference is presented by Marcum LLP, a top national accounting and
advisory firm registered with the Public Company Accounting Oversight
Board (PCAOB). Marcum’s Assurance Division provides the most up-to-date
service and guidance on SEC accounting and reporting issues. Services
include Financial Statement Audits in accordance with PCAOB standards;
Tax Compliance and Advisory Services; Due Diligence; Agreed-Upon
Procedures and Other Attest Work; Internal Audit Services;
Sarbanes-Oxley Section 404 Compliance Services and Software; Technical
Accounting Assistance; and IPO Assistance. For more information, visit

About Myomo Myomo, Inc. is a commercial stage medical
robotics Company that offers expanded mobility for those suffering from
neurological disorders and upper limb paralysis. Based on patented
technology developed at MIT and the Company, Myomo develops and markets
the MyoPro(R) product line of lightweight, non-invasive, powered arm
braces to restore function in the paralyzed or weakened arms and hands
of individuals that have suffered a stroke, spinal cord or nerve injury
such as brachial plexus injury, or other neuromuscular disability such
as amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS). It is
provided through clinical relationships with VA medical centers, leading
rehabilitation hospitals, and Orthotics and Prosthetics (“OP”)
practices. Several hundred have been successfully used by patients. It
is the only device that, sensing a patient’s own neurological signals
through non-invasive sensors on the arm, can restore their ability to
use their arms and hands so that they can return to work, live
independently and reduce their cost of care. Myomo is headquartered in
Cambridge, Massachusetts, with sales and clinical professionals across
the U.S. For more information, please visit

Forward Looking Statements This press release contains
forward-looking statements regarding the trading of the Company’s common
stock on the NYSE, the Company’s plans for the use of proceeds and
advancing its product line, increasing its sales and marketing efforts
and growing its business, and the Company’s future business
expectations, which are subject to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. These forward-looking
statements are only predictions and may differ materially from actual
results due to a variety of factors. Other risks and uncertainties
include, among others, risks related to the Company’s liquidity and
financial position, the trading of its common stock, its new products,
services, and technologies, government regulation and taxation, and
fraud. More information about factors that potentially could affect
Myomo’s business and financial results are included in Myomo’s filings
with the Securities and Exchange Commission. The Company cautions
readers not to place undue reliance on any such forward-looking
statements, which speak only as of the date made. The Company disclaims
any obligation subsequently to revise any forward-looking statements to
reflect events or circumstances after the date of such statements or to
reflect the occurrence of anticipated or unanticipated events.

View source version on

SOURCE: Myomo, Inc.”
Property FormalName=”PrimaryTwitterHandle” Value=”@myomoinc

For Myomo: 
Investor Relations: 
PCG Advisory 
Vivian Cervantes, 212-554-5482

Copyright Business Wire 2017